Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
Relay Therapeutics, Inc. (RLAY) to report Q4 and full year 2023 financial results and corporate highlights on February 22, 2024.
02/15/2024 - 04:05 PM
CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2023 financial results and corporate highlights after the U.S. financial markets close on Thursday, February 22, 2024.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter .
Contact: mgoulart@relaytx.com
Media: dan@1abmedia.com
When will Relay Therapeutics (RLAY) report its Q4 and full year 2023 financial results?
Relay Therapeutics (RLAY) will report its fourth quarter and full year 2023 financial results after the U.S. financial markets close on Thursday, February 22, 2024.
What is Relay Therapeutics' (RLAY) focus as a company?
Relay Therapeutics (RLAY) is a clinical-stage precision medicine company that transforms the drug discovery process by combining computational and experimental technologies.
What technologies does Relay Therapeutics (RLAY) use?
Relay Therapeutics (RLAY) utilizes leading-edge computational and experimental technologies in its drug discovery process.
RLAY Rankings
#5186 Ranked by Stock Gains
RLAY Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Cambridge
About RLAY
relay therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. by placing protein motion at the heart of drug discovery, relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. headquartered in cambridge, mass., relay therapeutics is a private company launched in 2016. to date, relay therapeutics has raised $120m in financing from third rock ventures, bvf partners, gv (formerly google ventures), an affiliate of d.e. shaw research, casdin capital, ecor1 capital, section 32 and alexandria venture investments. our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. if you're creative, collaborative and passionate
